Longeveron Inc. (LGVN): Nasdaq/NYSE listing notice — Longeveron director Richard Kender resigns; audit committee loses financial expert

Longeveron Inc.

Richard Kender resigned from Board and Audit Committee effective March 3, 2026, due to becoming Executive Chairman and Interim CEO of Seres Therapeutics.
Board appointed Dr. Roger Hajjar to Audit Committee on March 4, but no member currently qualifies as audit committee financial expert.
Company plans to appoint or submit for election a qualified director by next annual meeting or within 180-day cure period.
Kender's resignation not due to any disagreement with the Company's operations, policies, or management.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Longeveron Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(2), 5605(c)(4)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: audit committee
Rules: 5605(c)(2)(A), 5605(c)(2), 5605(c)(4)

Exact text from the filing

March 4, 2026 Longeveron Inc. (the “Company”) notified Nasdaq that, as a result of the resignation of Mr. Richard Kender as a member of the Board of Directors (the “Board”) of the Company and as chairman of the Audit Committee and the audit committee financial expert, as described below, the Company temporarily was no longer in compliance with Nasdaq Listing Rule 5605(c)(2)(A), which requires that the audit committee of a listed company be composed of at least three independent directors and that at least one member qualifies as an audit committee financial expert. On March 4, 2026, the Compan

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Longeveron Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-024839

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.